The Access Study
Currently Recruiting
9 Nov 2026
Up to $3,900
Brisbane, Australia
The study drug is a potential new medicine being developed to treat certain rare autoimmune diseases. These diseases are linked to a specific type of harmful antibody in the body. The study drug is believed to work by selectively removing only the harmful antibodies, while leaving the rest of your immune system healthy and intact. This targeted approach may lead to better results and fewer side effects than current treatments.
Your involvement contributes to making future treatments more targeted, accessible, and patient-friendly—potentially helping thousands of people around the world. It’s a meaningful way to support medical progress and make a lasting impact on the lives of others.
Join our clinical trial
This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee.
Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.
Why participate?
· Contribute to Research that supports autoimmunity.
· Help Make Treatments More Inclusive and Effective
· Be the Reason Better Treatments Move Forward
Study schedule
| Intake 1 | In-clinic stay:
9 November 2026 – 13 November 2026 |
Follow-up visits:
17 November 2026 – 8 December 2026 |
| Intake 2 | In-clinic stay:
11 November 2026 – 15 November 2026 |
Follow-up visits:
19 November 2026 – 10 December 2026 |
Study dates are subject to change. Our team will confirm details with you during the screening process.
Trial details
Study duration
- 4 night stay
- 4 follow-up visits
Study medication
Participants will receive the study drug as an intravenous (IV) infusion.
Additional eligibility
· Weigh between 40kg and 120kg.
· Non-smokers (no tobacco or nicotine use for at least 1 month), or smoking no more than 5 cigarettes per week.
· Prescription medications must be complete 14 days prior to admission (with some exceptions)
· Not pregnant or breastfeeding
· Willing to follow contraception guidelines (if applicable)
· Able to attend all study visits and follow instructions
Ethics
An independent ethics committee has approved this clinical trial.
Are you a match?
Age
18 - 64 years old
Remuneration
Up to $3,900 *with screening reimbursement.
Full details outlined in consent form.
Gender
Male, Female, Female (Post-menopausal) or Female of non-childbearing potential
BMI
BMI 18.5 - 32 kg/m2
Commitment
4 nights, 4 clinic visits
Medical condition
Not taking any medications